GlassScriptPhysician profile
Razan Asaad
NPI 1497048391
$8,476.62
in general payments reported to CMS, 2019-2025
20 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $3,944 · 2021: $2,282 · 2022: $396 · 2023: $146 · 2024: $241 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.15 |
| Education | $169.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,404.47 | 2019-2021 | |
| Novo Nordisk INC | $659.78 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $448.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $303.76 | 2022-2025 | Breztri, Lokelma, Airsupra |
| Amgen INC. | $264.56 | 2020-2025 | Repatha |
| Lundbeck LLC | $210.41 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $200.37 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.06 | 2019-2021 | |
| Pfizer INC. | $154.01 | 2025 | |
| Horizon Therapeutics Plc | $145.85 | 2022 | |
| Esperion Therapeutics, INC. | $140.20 | 2021 | |
| Phathom Pharmaceuticals, INC. | $124.74 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.73 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $49.07 | 2025 | Symbravo |
| Astellas Pharma US INC | $33.83 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27.26 | 2019 | |
| Phadia US INC. | $18.45 | 2025 | Immunocap |
| Exact Sciences Corporation | $16.51 | 2025 | The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $16.08 | 2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Razan Asaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.